March 28 (Reuters) - Eli Lilly and Co LLY.N:
PHASE 3B DATA PRESENTED AT AAD ANNUAL MEETING SHOW LILLY'S TALTZ (IXEKIZUMAB) PLUS ZEPBOUND (TIRZEPATIDE) DELIVERED SUPERIOR EFFICACY FOR ADULTS WITH PSORIATIC ARTHRITIS AND OBESITY
ELI LILLY - TALTZ AND ZEPBOUND MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS FOR STATISTICAL SUPERIORITY TO TALTZ MONOTHERAPY AT 36 WEEKS